Peripheral neuropathic pain
Conditions
Interventions
none
Sponsors
DAIICHI SANKYO CO., LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with peripheral neuropathic pain not treated with Tarlige tablet before 2.Patients with 12 or more points in the neuropathic pain screening questionnaire 3.Patients with pain lasting more than 3 months 4.Patients with a pain scale of 40 mm or more on VAS before administration of Tarlige tablet 5.Patients who started administration of Tarlige tablet during the contract period (contract period based on the contract with each medical site) 6.Patients who started administration of Tarlige tablet during the registration period 7.Patients from whom written informed consent was obtained
Exclusion criteria
Exclusion criteria: 1.Patients with a pain scale of 90 mm or less on VAS before administration of Tarlige tablet 2.Patients with other pain unrelated to PNP, that may confound the assessment of PNP 3.Patients with Neurologic disorders (depression, bipolar disorder, schizophrenia, etc.) 4.Patients with dementia, etc. who cannot respond appropriately to questionnaires and VAS for pain
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy The 50% responder rate of VAS for pain | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy 1)The 30% responder rate of VAS for pain 2)SF-8 score change from baseline for each domain 3)The 50% responder rate of VAS for sleep-interference 4)The 30% responder rate of VAS for sleep-interference 5)Ratio of 'very much improved' or 'much improved' in PGIC 6)Ratio of 'very much improved', 'much improved' or 'minimally improved' in PGIC | — |
Countries
Japan
Contacts
Public ContactGPSP Contact
GPSP for Contact
Outcome results
None listed